文献速递烧伤创面修复

静脉依前列醇治疗冻伤:加拿大烧伤中心质量改进与实施报告

A Protocolized Intravenous Epoprostenol Pathway for Frostbite: A Canadian Burn Center Quality Improvement and Implementation Report.
PubMed 文献 · J Burn Care Res · 2026-01-01

路径可行且总体耐受良好,但结果仅为描述性和假设生成性。

要点

  • 静脉依前列醇路径整合快速复温、分级、抗血栓素治疗及监测,可行且耐受良好。
  • 216个受累指趾中153个保留,2级65指保留62指,3级100指保留74指,4级41指保留7指。

核心结论

  • 协议引导的静脉依前列醇治疗冻伤可行且总体耐受良好,但结果仅为描述性和假设生成性,非疗效证据。

主要发现

  • 216个受累指趾中153个得以保留,其中2级65指保留62指,3级100指保留74指,4级41指保留7指。
  • 9例患者出现记录的不良反应或剂量限制性症状,经减量或暂时中断管理。

关键数值与推荐

  • 路径包括快速复温、分级、局部和全身抗血栓素治疗、资格标准、剂量滴定、生理监测、剂量调整、多学科护理和随访。
  • 现有记录未发现溶栓治疗、因不良反应永久停药或2级再评估,也未发现严重药物相关不良事件。

临床怎么用

  • 对于Cauchy 2-4级冻伤,可考虑在监测下使用静脉依前列醇路径,并配合快速复温和抗血栓素治疗。
  • 治疗期间应进行剂量滴定和生理监测,出现不良反应或剂量限制性症状时减量或暂时中断。

局限性

  • 回顾性描述性设计,样本量23例,结果应视为假设生成性而非疗效证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Severe frostbite is a dynamic microvascular injury that can progress to delayed tissue loss despite appropriate initial care. Contemporary management emphasizes rapid rewarming, antithromboxane therapy, clinical grading, selective thrombolysis, and prostacyclin-based treatment. Iloprost is the prostacyclin analogue most often described, but access may be delayed in some Canadian settings. We developed and implemented a monitored intravenous epoprostenol pathway for Cauchy grade 2-4 frostbite and retrospectively evaluated 23 patients treated between December 2017 and November 2025. The pathway incorporated rapid rewarming, grading, topical and systemic antithromboxane therapy, eligibility criteria, dose titration, physiologic monitoring, dose modification, multidisciplinary care, and follow-up. Overall, 153 of 216 affected digits were preserved. Preservation varied by severity: 62 of 65 grade 2 digits, 74 of 100 grade 3 digits, and 7 of 41 grade 4 digits were preserved. Twelve patients avoided amputation altogether. Mean treatment duration was 3.8 days, and most patients reached 8 ng/kg/min at least once. Documented adverse effects or dose-limiting symptoms occurred in 9 patients and were managed with dose reduction or temporary interruption. Available records did not identify thrombolytic therapy, permanent discontinuation for adverse reaction or grade 2 reassessment, or serious drug-attributed adverse events. Protocol-guided intravenous epoprostenol was feasible and generally well tolerated. Findings should be interpreted as descriptive and hypothesis-generating rather than evidence of treatment efficacy.

来源:J Burn Care Res,查看原文。版权归原作者所有。

引用

  1. Natanson R, Adibfar A, Au A, et al. A Protocolized Intravenous Epoprostenol Pathway for Frostbite: A Canadian Burn Center Quality Improvement and Implementation Report. J Burn Care Res. 2026. PMID: 42417809. doi:10.1093/jbcr/irag117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。